The primary purpose of this role is to contribute to the definition, execution, and delivery of the Global Market Access and Pricing (GMAP) strategy for amlitelimab in Atopic Dermatitis, with a clear focus on end-to-end launch readiness aligned to the Sanofi Integrated Launch Cycle (SILC).
Base: $178,500.00 - $257,833.33; Bonus/Equity: Not specified; Benefits: Not specified
Must-have
Nice-to-have
Not specified
Discover valuable connections who might provide insights and referrals.
Get 3x more responses when you reach out individually.